After the Weight Comes Off: Treating GLP-1-Related Skin Laxity with Sofwave
SYDNEY, Sept. 22, 2026 /PRNewswire/ -- Across cosmetic and dermatology clinics, a new patient profile is becoming increasingly familiar. Someone who has lost a significant amount of weight on a GLP-1 medication and is thrilled with the overall...
Novo receives Singapore approval for Wegovy® as first treatment for MASH with liver fibrosis
ESSENCE trial data showed 63% of participants receiving semaglutide achieved steatohepatitis resolution without worsening of liver fibrosis, compared with 34% receiving placebo, at Week 72. Singapore's Health Sciences Authority (HSA) has approved...
Novo Nordisk Launches Wegovy® in Hong Kong for Weight Management
Wegovy® (semaglutide) is a once-weekly injectable prescription medicine used in combination with a reduced calorie diet and increased physical activity for adults and adolescents aged 12 years old or above with obesity or adults with overweight in...
Fibronostics Acquires Stone Clinical Laboratories to Advance MASH/MASLD Diagnostics
Acquisition expands U.S. lab operations and accelerates innovation in non-invasive diagnostics for metabolic and liver diseases. NEW ORLEANS, Oct. 27, 2025 /PRNewswire/ -- Fibronostics, a global leader in non-invasive diagnostics for metabolic and...